EEF2K
関連文献

“Identification of the major Mr 100,000 substrate for calmodulin-dependent protein kinase III in mammalian cells as elongation factor-2”. The Journal of Biological Chemistry 262 (36):  17299–303. (Dec 1987). doi:10.1016/S0021-9258(18)45377-X. PMID 3693353.
“Regulation of elongation factor-2 by multisite phosphorylation”. European Journal of Biochemistry 213 (2):  689–99. (Apr 1993). doi:10.1111/j.1432-1033.1993.tb17809.x. PMID 8386634.
“Mapping the functional domains of elongation factor-2 kinase”. Biochemistry 39 (40):  12216–24. (Oct 2000). doi:10.1021/bi0007270. PMID 11015200.
“Phosphorylation of elongation factor-2 kinase on serine 499 by cAMP-dependent protein kinase induces Ca2+/calmodulin-independent activity”. The Biochemical Journal 353 (Pt 3):  621–6. (Feb 2001). doi:10.1042/0264-6021:3530621. PMC 1221608. PMID 11171059. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1221608/.
“A novel method to identify protein kinase substrates: eEF2 kinase is phosphorylated and inhibited by SAPK4/p38delta”. The EMBO Journal 20 (16):  4360–9. (Aug 2001). doi:10.1093/emboj/20.16.4360. PMC 125581. PMID 11500363. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC125581/.
“Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase”. The EMBO Journal 20 (16):  4370–9. (Aug 2001). doi:10.1093/emboj/20.16.4370. PMC 125559. PMID 11500364. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC125559/.
“Detection of anti-elongation factor 2 kinase (calmodulin-dependent protein kinase III) antibodies in patients with systemic lupus erythematosus”. Biochemical and Biophysical Research Communications 293 (3):  1073–6. (May 2002). doi:10.1016/S0006-291X(02)00324-8. PMID 12051769.
“Expressed sequence tag analysis of human RPE/choroid for the NEIBank Project: over 6000 non-redundant transcripts, novel genes and splice variants”. Molecular Vision 8:  205–20. (Jun 2002). PMID 12107410.
“Stress-induced regulation of eukaryotic elongation factor 2 kinase by SB 203580-sensitive and -insensitive pathways”. The Biochemical Journal 367 (Pt 2):  525–32. (Oct 2002). doi:10.1042/BJ20020916. PMC 1222910. PMID 12171600. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1222910/.
“Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398”. The Journal of Biological Chemistry 279 (13):  12220–31. (Mar 2004). doi:10.1074/jbc.M309773200. PMID 14709557.
“A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin”. Molecular and Cellular Biology 24 (7):  2986–97. (Apr 2004). doi:10.1128/MCB.24.7.2986-2997.2004. PMC 371112. PMID 15024086. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC371112/.
“Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry”. Analytical Chemistry 76 (10):  2763–72. (May 2004). doi:10.1021/ac035352d. PMID 15144186.
“Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain”. The FEBS Journal 272 (16):  4211–20. (Aug 2005). doi:10.1111/j.1742-4658.2005.04833.x. PMID 16098202.
“Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes”. Genome Research 16 (1):  55–65. (Jan 2006). doi:10.1101/gr.4039406. PMC 1356129. PMID 16344560. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1356129/.
“Elongation factor-2 kinase: its role in protein synthesis and autophagy”. Autophagy 2 (4):  294–6. (2007). doi:10.4161/auto.2857. PMID 16921268.
“A probability-based approach for high-throughput protein phosphorylation analysis and site localization”. Nature Biotechnology 24 (10):  1285–92. (Oct 2006). doi:10.1038/nbt1240. PMID 16964243.
“Global, in vivo, and site-specific phosphorylation dynamics in signaling networks”. Cell 127 (3):  635–48. (Nov 2006). doi:10.1016/j.cell.2006.09.026. PMID 17081983.